89Bio Q3 2023 Earnings Report

89bio reported financial results for Q3 2023 and provided corporate updates.

Key Takeaways

89bio reported a net loss of $34.7 million for the third quarter ended September 30, 2023. As of September 30, 2023, the company's cash, cash equivalents and short-term available-for-sale securities totaled $448.3 million. The FDA granted Breakthrough Therapy Designation to pegozafermin for NASH with fibrosis.

FDA granted Breakthrough Therapy Designation to pegozafermin for the treatment of NASH with fibrosis.

Data from ENLIVEN trial of patients with F4 NASH will be featured in an oral presentation during AASLD The Liver Meeting.

Company expects to receive feedback from regulatory agencies on the pegozafermin Phase 3 NASH development program this quarter.

Enrollment continues to progress in ENTRUST, the Phase 3 trial evaluating pegozafermin in patients with SHTG.

Previous year: -$0.57

-21.1%

Gross Profit

$0